GLP-1 Receptor Agonist Comparison 2026

Tirzepatide (Mounjaro/Zepbound) shows the highest average weight loss in clinical trials and 2025-2026 real-world data: SURMOUNT-1 trial reported 22.5% mean body weight loss at 72 weeks for patients without diabetes on the 15mg dose; the SURMOUNT-OSA 2024 trial showed 18-20% reduction. Semaglutide (Wegovy/Ozempic off-label) reports 14.9% mean loss at 68 weeks (STEP-1 trial) on the 2.4mg dose. Liraglutide (Saxenda) shows 8% mean loss at 56 weeks. Real-world adherence-adjusted: actual weight loss tends to be 60-75% of trial-stated values due to discontinuation, dose interruptions, and tolerance development. Tirzepatide's dual GIP+GLP-1 mechanism appears responsible for the superior outcomes vs single-receptor GLP-1 agents.

List prices (April 2026, USA): Wegovy $1,349/month, Ozempic $968/month, Rybelsus $968/month, Mounjaro $1,069/month, Zepbound $1,059/month, Saxenda $1,349/month. Manufacturer savings cards reduce out-of-pocket dramatically: Novo Nordisk's Ozempic/Wegovy/Saxenda savings card brings copay to as low as $25/month for commercially insured patients; Eli Lilly's Mounjaro/Zepbound savings card brings copay to as low as $25/month with active commercial coverage and as low as $549/month without coverage (Zepbound direct-to-patient program launched September 2024). Compounded semaglutide and tirzepatide from 503A pharmacies cost $200-$450/month — but the FDA's May 2024 ruling removed both from the shortage list, leading to enforcement actions against compounders in late 2024 and ongoing through 2026; current legal status varies by formulation and manufacturer claims.

As of April 2026, Medicare does NOT cover GLP-1s for obesity treatment alone — the 2003 Medicare Modernization Act explicitly excluded weight loss drugs from Part D coverage. EXCEPTION expanded in March 2024: Wegovy IS covered when prescribed for cardiovascular risk reduction in adults with established cardiovascular disease and BMI ≥27 (CMS National Coverage Determination 280.X). The Treat and Reduce Obesity Act (TROA) seeks to repeal the exclusion and allow standard Medicare obesity coverage; the bill cleared Senate Finance committee March 2026 with bipartisan support and is scheduled for floor vote summer 2026. Estimated Medicare cost if passed: $35-$50 billion over 10 years per CBO. Medicaid coverage is state-by-state — 18 states cover Wegovy or Zepbound for obesity in 2026 (up from 11 in 2024).

Most common (10%+ patients): nausea (44% on tirzepatide, 39% semaglutide), diarrhea (21-23%), constipation (17-23%), vomiting (10-15%), abdominal pain (10-12%), reduced appetite (designed effect, but some find unpleasant). Most resolve within 4-8 weeks as dose titrates up gradually. Less common but significant (1-5%): gallbladder issues (cholecystitis, gallstones — 2.6x risk vs placebo), hair shedding (telogen effluvium — typically resolves at 6-9 months once weight stabilizes), injection site reactions, dehydration. Rare/serious (<1%): pancreatitis (5-fold risk increase, monitored via lipase), diabetic retinopathy progression in pre-existing diabetics, suicidal ideation (FDA reviewing 2024 reports — current consensus is association, not causation), thyroid C-cell tumors (boxed warning — animal studies; human signal weak; contraindicated in MEN-2 and MTC family history). NEW 2026 concern: gastroparesis cases reported in litigation; Novo and Lilly added warnings December 2024.

Weight regain is well-documented. STEP-4 trial (semaglutide): patients who continued treatment maintained 81% of weight loss; those who switched to placebo regained two-thirds of lost weight within 1 year. SURMOUNT-4 (tirzepatide): patients continuing 15mg lost an additional 5.5% in extension; placebo group regained 14% within 12 months. Mechanism: GLP-1s suppress appetite-stimulating signals; once stopped, hunger normalizes within 4-6 weeks. The 2026 clinical consensus per Endocrine Society + Obesity Medicine Association: GLP-1 therapy is a long-term/lifetime treatment for obesity (similar to antihypertensives for blood pressure), NOT a temporary weight loss tool. Discontinuation strategies that minimize regain: gradual taper over 4-6 months, structured exercise program 3+x/week, behavioral therapy, consideration of "bridging" to lower-cost oral meds (Rybelsus 14mg, naltrexone-bupropion).

Yes, but the math is harder. STEP and SURMOUNT data show 25-40% of weight lost on GLP-1s comes from lean mass (vs 20-25% from natural caloric deficit). Mitigation strategies: (1) PROTEIN — 1.0-1.2 g/lb body weight (more than the 0.8 standard since absorption is reduced); spread over 4-5 meals to maximize muscle protein synthesis given suppressed appetite. (2) RESISTANCE TRAINING — 3-4 sessions per week, progressive overload critical — without it, lean mass loss approaches 50%. (3) ADEQUATE TOTAL CALORIES — many patients on GLP-1s drop to 800-1,200 calories/day inadvertently due to appetite suppression; aim for 12 calories per pound minimum to support lean mass retention. (4) CREATINE SUPPLEMENTATION — 5g/day, well-tolerated, supports anaerobic capacity. Body composition tracking via DEXA every 3-6 months is more useful than scale weight on these medications.

Compounded semaglutide and tirzepatide were widely available 2022-2024 due to FDA-declared shortages allowing 503A and 503B pharmacies to compound. FDA removed semaglutide from shortage list April 2024 and tirzepatide October 2024, triggering enforcement actions — most major compounders (Hims, Mochi, Ro, EmpowerRx) shifted to compounded LIRAGLUTIDE or to "salt forms" (semaglutide acetate vs the FDA-approved sodium salt) which the FDA argues are NOT pharmaceutically equivalent. Q1 2026 status: ongoing litigation (Novo Nordisk v. multiple compounders, Eli Lilly v. compounders); 503B compounding remains restricted; some 503A pharmacies operate under state-level prescribing exceptions. QUALITY concerns: independent testing by Cayman Chemical 2024 found 12 of 31 sampled compounded products had concentration errors >15% from labeled dose; sterility issues reported in 8/31 samples. RECOMMENDATION: branded products via savings cards remain the safest path; verify any compounded source through state board of pharmacy registration and request third-party potency/sterility testing certificates.

Typical timeline based on STEP/SURMOUNT trial data and clinical experience: WEEK 1-4 (titration phase, 0.25mg semaglutide / 2.5mg tirzepatide): mild appetite suppression, 1-3 lbs loss, side effects peak. WEEK 5-12 (titrating to therapeutic dose): 5-10 lbs loss typical, appetite suppression noticeable, food preferences shift toward lower volume. MONTH 4-6 (therapeutic maintenance): 8-15% body weight loss range, plateau at first appears around month 5 — push through with dose increase or non-pharmacologic adjustments. MONTH 7-12: peak weight loss typically reached month 12-15; total 15-22% loss for tirzepatide users adherent to lifestyle program, 12-15% for semaglutide. Patients who DO NOT lose 5%+ at month 6 are unlikely to be high responders and should consider switching mechanism (semaglutide → tirzepatide, or to combination therapy). Body composition lags behind scale weight by 4-8 weeks; DEXA at baseline + month 6 provides best progress tracking.